相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study
Christian Taucher et al.
VACCINE (2019)
Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading
Luis Filgueira et al.
PATHOGENS (2019)
Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose
Vera Kadlecek et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016
William L. Walker et al.
VACCINE (2018)
Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study
Tomas Jelinek et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2018)
Effectiveness of Japanese encephalitis SA 14-14-2 live attenuated vaccine among Indian children: Retrospective 1:4 matched case-control study
Babasaheb V. Tandale et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2018)
Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region
Katrin L. Dubischar et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children An Open-label, Randomized, Active-controlled, Phase 3 Study
Katrin L. Dubischar et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults
Yuka Saito et al.
BMC INFECTIOUS DISEASES (2016)
Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study
Jakob P. Cramer et al.
VACCINE (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity
Kuan Rong Chan et al.
NATURE MICROBIOLOGY (2016)
The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis
Elina O. Erra et al.
EXPERT REVIEW OF VACCINES (2015)
Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study
Tomas Jelinek et al.
JOURNAL OF TRAVEL MEDICINE (2015)
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012
Ingrid B. Rabe et al.
VACCINE (2015)
Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis
Maria Paulke-Korinek et al.
VACCINE (2015)
Product review on the JE vaccine IXIARO
Christa Firbas et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, multi-center study
Martin Alberer et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2014)
Immunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review
Xing Li et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain
Arindam Sarkar et al.
BMC INFECTIOUS DISEASES (2013)
Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes
Elina O. Erra et al.
CLINICAL INFECTIOUS DISEASES (2013)
Recurrence of Japanese Encephalitis Epidemic in Wuhan, China, 2009-2010
Quan Hu et al.
PLOS ONE (2013)
Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: A two-year follow-up study
Elina O. Erra et al.
VACCINE (2013)
A Single Dose of Vero Cell-Derived Japanese Encephalitis (JE) Vaccine (Ixiaro) Effectively Boosts Immunity in Travelers Primed With Mouse Brain-Derived JE Vaccines
Elina O. Erra et al.
CLINICAL INFECTIOUS DISEASES (2012)
Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: A case-control study
Charung Muangchana et al.
VACCINE (2012)
Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine
Tabitha Woolpert et al.
VACCINE (2012)
Effectiveness of the Viet Nam Produced, Mouse Brain-Derived, Inactivated Japanese Encephalitis Vaccine in Northern Viet Nam
Florian Marks et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Isolation and Genetic Characteristics of Human Genotype 1 Japanese Encephalitis Virus, China, 2009
Jiu-Song Zhang et al.
PLOS ONE (2011)
Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51
Susanne Eder et al.
VACCINE (2011)
Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers
Yvonne Van Gessel et al.
VACCINE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51
Katrin Dubischar-Kastner et al.
VACCINE (2010)
Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age
A. Kaltenboeck et al.
VACCINE (2010)
Japanese Encephalitis Vaccine (Inactivated, Adsorbed) [IXIARO (R)]
Sean T. Duggan et al.
DRUGS (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Japanese Encephalitis in Travelers: Review of Cases and Seasonal Risk
Mads R. Buhl et al.
JOURNAL OF TRAVEL MEDICINE (2009)
Effectiveness of One Dose of SA 14-14-2 Vaccine against Japanese Encephalitis
Rashmi Kumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study
Elisabeth Schuller et al.
VACCINE (2009)
Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study
A. Kaltenboeck et al.
VACCINE (2009)
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine
E. Tauber et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study
E. Schuller et al.
VACCINE (2008)
Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51
Elisabeth Schuller et al.
VACCINE (2008)
Safety and immunogenicity of a Vero-cell-derived,inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
E. Tauber et al.
LANCET (2007)
A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis
Arthur Lyons et al.
VACCINE (2007)
Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004
J Hombach et al.
VACCINE (2005)
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
DWC Beasley et al.
VACCINE (2004)
Japanese encephalitis vaccine for travelers: Exploring the limits of risk
DR Shlim et al.
CLINICAL INFECTIOUS DISEASES (2002)
Neutralizing peptide ligands selected from phage-displayed libraries mimic the conformational epitope on domain III of the Japanese encephalitis virus envelope protein
SC Wu et al.
VIRUS RESEARCH (2001)
分享论文
